Table 3

Clinical Outcomes at 30 Days in Male and Female Patients

Male Patients (n = 6,172)Female Patients (n = 2,232)Rate Ratio (95% CI) (Unadjusted)Unadjusted p ValueRate Ratio (95% CI) (Adjusted)Adjusted p Value
Death, MI, stroke560 (9.1)238 (10.7)0.84 (0.72–0.98)0.0301.04 (0.88–1.22)0.67
Death, MI, stroke, BARC type 3 or 5624 (10.2)272 (12.2)0.82 (0.70–0.95)0.00711.02 (0.88–1.20)0.76
Death, MI, stroke, BARC type 3 or 5, TVR, ST636 (10.4)274 (12.3)0.83 (0.71–0.96)0.0111.03 (0.88–1.20)0.74
Death91 (1.5)66 (3.0)0.49 (0.36–0.68)<0.00010.80 (0.56–1.16)0.24
Death cardiovascular88 (1.4)61 (2.7)0.52 (0.37–0.72)0.00010.82 (0.56–1.19)0.30
MI460 (7.5)169 (7.6)0.98 (0.81–1.17)0.801.11 (0.92–1.34)0.29
Stroke20 (0.3)12 (0.5)0.60 (0.29–1.22)0.150.75 (0.33–1.71)0.49
TIA6 (0.1)12 (0.5)0.18 (0.07–0.48)0.00010.31 (0.10–0.91)0.033
TVR65 (1.1)24 (1.1)0.97 (0.61–1.55)0.900.88 (0.53–1.47)0.63
ST definite45 (0.7)12 (0.5)1.35 (0.71–2.55)0.361.32 (0.67–2.59)0.43
 Acute26 (0.4)7 (0.3)1.34 (0.58–3.08)0.501.15 (0.48–2.78)0.75
 Subacute20 (0.3)5 (0.2)1.43 (0.54–3.81)0.471.65 (0.58–4.71)0.35
ST definite/probable63 (1.0)17 (0.8)1.33 (0.78–2.27)0.301.45 (0.81–2.57)0.21
 Acute30 (0.5)8 (0.4)1.35 (0.62–2.95)0.451.24 (0.54–2.85)0.61
 Subacute35 (0.6)9 (0.4)1.39 (0.67–2.89)0.381.82 (0.83–4.02)0.14
Bleeding654 (10.7)302 (13.7)0.76 (0.66–0.88)0.00020.87 (0.75–1.01)0.067
 BARC type 1327 (5.3)147 (6.8)0.79 (0.65–0.96)0.0200.84 (0.68–1.04)0.11
 BARC type 2238 (3.9)104 (4.7)0.82 (0.65–1.03)0.0900.92 (0.71–1.18)0.51
 BARC type 393 (1.6)45 (2.0)0.74 (0.52–1.05)0.0941.06 (0.72–1.56)0.77
 BARC type 3a47 (0.8)26 (1.2)0.65 (0.40–1.04)0.0721.03 (0.61–1.75)0.91
 BARC type 3b42 (0.7)18 (0.8)0.84 (0.48–1.45)0.521.11 (0.61–2.03)0.73
 BARC type 3c5 (0.1)1 (0.0)1.79 (0.21–15.36)0.591.55 (0.14–16.68)0.72
 BARC type 410 (0.2)2 (0.1)1.79 (0.39–8.17)0.452.12 (0.43–10.48)0.36
 BARC type 56 (0.1)15 (0.7)0.14 (0.06–0.37)<0.00010.17 (0.06–0.50)0.0012
 BARC type 5a3 (0.0)12 (0.5)0.09 (0.03–0.32)<0.00010.13 (0.03–0.51)0.0036
 BARC type 5b3 (0.0)3 (0.1)0.36 (0.07–1.78)0.190.25 (0.04–1.63)0.15
 BARC type 3 or 599 (1.6)60 (2.7)0.59 (0.43–0.81)0.00110.84 (0.59–1.19)0.32
 BARC type 3 or 5 access site33 (0.6)26 (1.2)0.45 (0.27–0.76)0.00200.65 (0.37–1.16)0.14
 BARC type 3 or 5 non–access site66 (1.1)34 (1.5)0.70 (0.46–1.05)0.0840.97 (0.62–1.53)0.90
 BARC type 2, 3, or 5335 (5.5)161 (7.3)0.74 (0.61–0.90)0.00190.90 (0.73–1.10)0.29
 BARC type 2, 3, or 5 access site165 (2.7)101 (4.6)0.58 (0.45–0.74)<0.00010.64 (0.49–0.85)0.0016
 BARC type 2, 3, or 5 non–access site176 (2.9)60 (2.7)1.06 (0.79–1.42)0.711.39 (1.01–1.90)0.042
 TIMI major38 (0.6)25 (1.1)0.54 (0.33–0.90)0.0170.68 (0.39–1.20)0.18
 TIMI minor32 (0.6)24 (1.1)0.48 (0.28–0.81)0.00500.75 (0.42–1.36)0.35
 TIMI major/minor70 (1.2)49 (2.2)0.51 (0.35–0.74)0.00020.71 (0.47–1.07)0.10
 GUSTO severe32 (0.5)18 (0.8)0.64 (0.36–1.14)0.120.91 (0.48–1.72)0.77
 GUSTO moderate31 (0.5)24 (1.1)0.46 (0.27–0.79)0.00360.65 (0.36–1.17)0.15
 GUSTO mild591 (9.7)264 (12.1)0.79 (0.68–0.92)0.00200.88 (0.75–1.03)0.11
 GUSTO moderate/severe63 (1.0)42 (1.9)0.54 (0.36–0.79)0.00150.74 (0.48–1.14)0.18
Composite of surgical access site repair and blood transfusion61 (1.0)53 (2.4)0.41 (0.28–0.59)<0.00010.56 (0.37–0.84)0.0056
Surgical access site repair11 (0.2)8 (0.4)0.49 (0.20–1.22)0.120.49 (0.18–1.32)0.16
Blood transfusion55 (0.9)49 (2.2)0.40 (0.27–0.59)<0.00010.56 (0.37–0.87)0.0089

Values are n (%), unless otherwise indicated.

BARC = Bleeding Academic Research Consortium; CI = confidence interval; GUSTO = Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries; ST = stent thrombosis; TVR = other abbreviations as in Tables 1 and 2.